Botulinum Toxin (BTX) cosmetic is one of the most extensively studied dermatology and is approved for cosmetic use in 78 countries. BTX-cosmetic has a record of experience that aesthetic specialists know and trust. Additionally, the safety and efficacy of BTX-cosmetic have been evaluated in both Allergan sponsored clinical trials as well as in 417 peer-reviewed articles in scientific and medical journals. Approximately 10.9 million vials of BTX-cosmetic have been sold in the United States since 2002, and millions of people have already made BTX-cosmetic a part of what they do for themselves. Today, BTX-cosmetic is the number-one selling product of its kind in the world.
The efforts to use botulinum ingredient in cosmetics have continued in the cosmetics industry. However, botulinum compounds with a size of 900Kilo Dalton have not been penetrated by human skin and have been used through injections. Most existing Botox cosmetics use different ingredients other than actual botulinum, using Acetyl Hexapeptide and Syn-Ake ingredients. BPMed Cosmetic produced a BoLCA+ product that applies technology to penetrate the skin to 50Kilo Dalton of botulinum-derived ingredients. The botulinum technology, which was used in medicine for neuromuscular disease treatment and wrinkle treatment, has now been introduced into the cosmetics market. This is the result of cooperation between BPMed Cosmetic with a venture company that has a skin permeation technology. BoLCA+ has lifting, whitening and soothing effects through their mask, serum and cream.
Advantages of using botulinum through cosmetics rather than injections are as follows. First, it can keep off the problem of infection caused by injection. Second, it does not injure the skin, leaving no bruises and swelling. Third, it is not restricted by time and place. BPMed Cosmetic is currently in negotiations to advance into Europe, the United States, and Canada, beginning with an exclusive contract with domestic hospitals and five neighboring countries.
▲ BPMed Cosmetic Co., Ltd
▲ Brand Name : BoLCA+
▲ CEO : Ki-Young Yoon
▲ T : +82-2-1644-5865
▲ E-mail : kyyoon@bpmedcosmetic.com
▲ www.bpmedcosmetic.com / www.bolca.co.kr
Dean Lee
K-Herald Korea
(Los Angeles Times Advertising Supplement)
